Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) is a clinical-stage biopharmaceutical company focused on inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). Its news flow centers on the development of its lead antibody candidate, rademikibart, and on corporate and regulatory milestones that shape the company’s trajectory.
Readers following CNTB news can expect regular updates on clinical progress, including recruitment status and topline data timing for the Phase 2 Seabreeze STAT asthma and Seabreeze STAT COPD studies, which evaluate rademikibart as an adjunct treatment for acute exacerbations. Company announcements also highlight new mechanism of action findings, post-hoc analyses of Phase 2b asthma data, and presentations at major medical meetings such as the European Respiratory Society Congress, the American Thoracic Society International Conference, and the European Academy of Allergy and Clinical Immunology Congress.
News items frequently cover regulatory and partnership developments, including the exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd. in Greater China and the submission and acceptance of a New Drug Application for rademikibart for atopic dermatitis by China’s National Medical Products Administration. Investors also see coverage of capital markets actions, such as the termination of the company’s American Depositary Receipt program and the direct listing of its ordinary shares on the Nasdaq Global Market under the symbol CNTB.
Additional CNTB news includes financial results, board appointments, and community initiatives, such as the collaboration with the Jovante Woods Foundation to expand asthma education programs. For investors, analysts, and healthcare observers, this news page provides a centralized view of Connect Biopharma’s clinical, regulatory, financial, and outreach activities related to rademikibart and its broader inflammatory disease focus.
Connect Biopharma (NASDAQ: CNTB) reported 2025 results and a business update on March 31, 2026. Key items: positive Phase 1 IV rademikibart topline with rapid FEV1 gains (~200–400 mL maintained to Day 29); Phase 3 AD results showed near‑maximal responses in ~90% through 52 weeks; Phase 2 Seabreeze STAT studies ongoing with toplines mid‑2026.
Corporate: entered a $20.2M private placement (6,130,000 shares at $3.25); cash $44.3M at Dec 31, 2025; expected runway into H2 2027. FY2025 net loss $55.5M; R&D $37.8M; license revenues $64k; eligible milestones ~ $110M.
Connect Biopharma (Nasdaq: CNTB) agreed to sell 6,130,000 ordinary shares in a private placement at $3.25 per share, expected to raise gross proceeds of approximately $20.2 million.
The financing, led by Panacea Venture with Leerink Partners and Cantor as joint placement agents, is expected to close on or about March 31, 2026 and extend the company’s cash runway into the second half of 2027. Net proceeds will fund R&D, development programs, working capital and general corporate purposes.
Connect Biopharma (Nasdaq: CNTB) reported Phase 3 RADIANT-AD results for rademikibart, presented at AAD 2026. In a 52-week trial (n=259), rademikibart achieved durable responses: EASI-75 96.6%, IGA 0/1 87.1%, and EASI-90 85.3%, with safety comparable to placebo and low conjunctivitis rates.
The study used 300 mg SC every two weeks with a 16-week induction and 36-week maintenance phase; company to host a March 30, 2026 webcast and call.
Connect Biopharma (Nasdaq: CNTB) reported positive topline Phase 1 results for IV rademikibart (300 mg 2-minute IV push) in asthma and COPD patients on March 30, 2026. Patients showed rapid FEV1 gains (≥200 mL in many) within 15 minutes, with mean improvements ~200–400 mL maintained through Day 29. The drug was generally well tolerated with no serious or severe AEs. Connect is recruiting Phase 2 Seabreeze STAT studies for acute exacerbations and expects topline Phase 2 data mid-2026, then plans FDA discussions on a Phase 3 program.
Connect Biopharma (Nasdaq: CNTB) announced that results from a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis, conducted by partner Simcere, will be presented in the Late-Breaking Research session at the AAD Annual Meeting on March 28, 2026.
The presentation (RADIANT-AD) is scheduled for March 28, 2026, 9:48–10:00 a.m. MDT at Bellco Theatre 3. According to Connect Biopharma, the Phase 3 data provide a strong basis for Simcere’s pending NDA in China and highlight rademikibart’s potentially differentiated safety and efficacy, supporting future AD development outside China.
Connect Biopharma (Nasdaq: CNTB) management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
A live webcast will be available via the company investor website and an archived replay will remain accessible for approximately 90 days.
Connect Biopharma (Nasdaq: CNTB) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast will be available via the Investors section of the company website at investors.connectbiopharma.com, with an archived replay accessible for approximately 90 days after the conference.
Connect Biopharma (Nasdaq: CNTB) highlighted new mechanism‑of‑action data for rademikibart and outlined 2026 priorities, emphasizing clinical execution. Mechanistic studies show enhanced IL‑4R binding, greater internalization versus dupilumab, and stronger rescue of β‑agonist responsiveness in human airway models, supporting faster, larger FEV1 improvements observed previously. Ongoing Phase 1b IV study has shown preliminary faster FEV1 increases versus subcutaneous dosing with topline results expected in Q1 2026. Phase 2 Seabreeze STAT asthma and COPD trials are recruiting with topline data expected mid‑2026. Cash, cash equivalents and short‑term investments were $54.8M as of Sept 30, 2025, with runway into 2027 under current plans.
Connect Biopharma (Nasdaq: CNTB) announced that company management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 10:50 a.m. ET.
A live webcast will be available via the company's Investors website at investors.connectbiopharma.com, and an archived replay will be accessible on the site for approximately 90 days after the conference.
Connect Biopharma (Nasdaq: CNTB) reported third quarter 2025 results and a business update on Nov 12, 2025. Key developments include ongoing recruitment in Phase 2 Seabreeze STAT studies for acute asthma and COPD with topline data expected in 1H 2026, and presentation of positive Phase 2 asthma data at ERS 2025 showing larger lung-function gains in patients with baseline EOS ≥300 cells/μL and FeNO ≥25 ppb. Connect’s Greater China licensee, Simcere, had its NDA for rademikibart in atopic dermatitis accepted by China’s NMPA in July 2025; Connect is eligible for up to $110 million of remaining milestone payments plus tiered royalties. Corporate actions included terminating the ADR program and directly listing ordinary shares on Nasdaq under CNTB. Cash and short-term investments were $54.8M at Sept 30, 2025, expected to fund operations into 2027.